Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering since 2022 and will use the proceeds to ...

When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

When Grammy-nominated singer-songwriter Aloe Blacc got COVID despite being vaccinated and boosted, he tried to fund research for a better solution. What he quickly found out? You can’t just write a ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Windlas Biotech approved a Rs 47 crore share buyback at Rs 1,000 per share via the tender route, with April 24 set as the ...